Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1451-1459

  Lv, Long ^a,b   Wang, Ping ^b   Zhou, Xiaoqing ^b   Sun, Beicheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Gaochun People's Hospital   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; P53 codon 72; Polymorphisms

Indexed keywords

ARGININE; PROLINE;

ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CODON; ETHNICITY; FAMILY HISTORY; GENDER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 84878689634     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0649-7     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev Anticancer Ther. 2001;1:277-90.
3. Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep. 2004;6:177-83.
4. Naugler WE, Schwartz JM. Hepatocellular carcinoma. Dis Mon. 2008;54:432-44.
5. Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2012. doi: 10.1016/j.canlet.2012.01.038.
6. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int. 2008;28:160-74.
7. Yam JW, Wong CM, Ng IO. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci (Schol Ed). 2010;2:117-34.
8. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993;262:1980-1.
9. Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5:405-9.
10. Yamashita T, Yaginuma Y, Saitoh Y, Kawai K, Kurakane T, Hayashi H, et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis. 1999;20:1733-6.
11. Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, et al. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol. 2012;33:927-33.
12. Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008;29:2120-5.
13. Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A. The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett. 2012;3:875-8.
14. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481-6.
15. Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256-66.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
19. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70-1.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
21. Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study. Mol Biol Rep. 2012;39:1639-47.
22. Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6:13.
23. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192-6.
24. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37:748-54.
25. Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett. 2005;229:77-83.
26. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 2004;208:75-9.
27. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193:199-205.
28. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697-702.
29. Zhang YY, Yu HP, Fan XJ. Association of p53 codon72 polymorphism and risk of hepatocellular carcinoma. J Chin Oncol. 2012;18:189-93 [Article in Chinese].
30. Zhu ZZ, Cong WM, Zhu GS, Liu SF, Xian ZH, Wu WQ. Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22:632-5 [Article in Chinese].
31. Peng T, Yan LN, Liu ZM, Shen HM, Ong CN, Peng MH, et al. Significant association of p53 codon 72 single neucletide polymorphism with hepatocellular carcinoma in Guangxi population. Chin J Surg. 2004;42:313-4 [Article in Chinese].
32. Hainaut P, Wiman KG. 30 years and a long way into p53 research. Lancet Oncol. 2009;10:913-9.
33. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer. 2011;129:920-30.
34. Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S. TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1840-7.
35. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-87.
36. Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int. 2005;25:220-5.
37. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26:153-61.
38. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286:52-9.